Apr 24, 2024 07:00AM

Mar 25, 2024 06:45AM

Mar 14, 2024 06:02AM

Mar 14, 2024 06:00AM

Jan 4, 2024 06:01AM

Jan 4, 2024 06:00AM

Dec 27, 2023 06:56AM First Wave BioPharma (FWBI) Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Dec 27, 2023 06:00AM

Dec 18, 2023 06:01AM

Dec 18, 2023 06:00AM

Sep 14, 2023 06:00AM

Sep 14, 2023 06:00AM

Jul 13, 2023 07:01AM

Jul 13, 2023 07:00AM First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation

Jul 5, 2023 07:00AM

Jul 5, 2023 07:00AM

May 22, 2023 08:00AM

Jan 31, 2023 07:05AM

Jan 31, 2023 07:00AM

Jan 25, 2023 07:03AM

Jan 25, 2023 07:00AM First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

Jan 13, 2023 04:00PM

Jan 13, 2023 04:00PM

Nov 30, 2022 07:00AM

Nov 16, 2022 07:03AM

Nov 16, 2022 07:00AM

Sep 19, 2022 07:00AM

Sep 7, 2022 07:00AM First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

Apr 27, 2022 07:05AM

Apr 27, 2022 07:00AM

Mar 28, 2022 04:24PM

Mar 28, 2022 04:23PM

Mar 3, 2022 07:00AM

Jan 6, 2022 07:00AM

Dec 13, 2021 07:08AM First Wave BioPharma (FWBI) Chairman and CEO Issues Letter to Shareholders

Dec 13, 2021 07:00AM

Nov 30, 2021 07:07AM

Nov 30, 2021 07:00AM

Oct 21, 2021 07:30AM

Oct 19, 2021 09:25AM

Oct 19, 2021 09:24AM

Oct 14, 2021 09:00AM First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Oct 12, 2021 08:30AM

Oct 4, 2021 11:45AM

Oct 1, 2021 12:30PM

Sep 28, 2021 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All